SG146649A1 - Mucoactive agents for treating a pulmonary disease - Google Patents

Mucoactive agents for treating a pulmonary disease

Info

Publication number
SG146649A1
SG146649A1 SG200806902-3A SG2008069023A SG146649A1 SG 146649 A1 SG146649 A1 SG 146649A1 SG 2008069023 A SG2008069023 A SG 2008069023A SG 146649 A1 SG146649 A1 SG 146649A1
Authority
SG
Singapore
Prior art keywords
pulmonary disease
treating
mucoactive agents
relates
present
Prior art date
Application number
SG200806902-3A
Other languages
English (en)
Inventor
David Morton
David Ganderton
John Staniforth
Yorick Kamlag
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0321611.6A external-priority patent/GB0321611D0/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of SG146649A1 publication Critical patent/SG146649A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG200806902-3A 2003-09-15 2004-09-15 Mucoactive agents for treating a pulmonary disease SG146649A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0321611.6A GB0321611D0 (en) 2003-09-15 2003-09-15 Pharmaceutical compositions
GBGB0327723.3A GB0327723D0 (en) 2003-09-15 2003-11-28 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
SG146649A1 true SG146649A1 (en) 2008-10-30

Family

ID=34315438

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200806902-3A SG146649A1 (en) 2003-09-15 2004-09-15 Mucoactive agents for treating a pulmonary disease

Country Status (15)

Country Link
US (2) US7928089B2 (no)
EP (2) EP1663151A2 (no)
JP (2) JP4913595B2 (no)
KR (1) KR20060082865A (no)
CN (1) CN1874757B (no)
AU (1) AU2004271778B2 (no)
BR (1) BRPI0414425A (no)
CA (1) CA2538399A1 (no)
GB (1) GB0327723D0 (no)
IL (1) IL173987A0 (no)
NO (1) NO20061254L (no)
NZ (1) NZ545550A (no)
RU (1) RU2363448C2 (no)
SG (1) SG146649A1 (no)
WO (1) WO2005025540A2 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
PL1694342T3 (pl) * 2003-11-12 2021-07-05 Trustees Of The University Of Pennsylvania Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
WO2005112970A2 (en) * 2004-05-12 2005-12-01 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat infections
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
PL3279663T3 (pl) 2006-03-15 2022-01-10 The Brigham And Women's Hospital, Inc. Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
RU2455021C2 (ru) * 2006-09-19 2012-07-10 Дискавери Лабораториз, Инк. Композиции легочных сурфактантов и способы их применения, содействующие очищению от слизи
CN101433521B (zh) * 2007-11-14 2012-08-08 中国医学科学院药用植物研究所 药用可吸入微粒、使用其的肺部吸入制剂及其制备方法
DK2250280T3 (en) 2008-01-25 2015-03-09 Gen Hospital Corp THERAPEUTIC USES OF gelsolin in renal failure
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
WO2010102066A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Dextran polymer powder for inhalation administration of pharmaceuticals
US9724664B2 (en) 2009-03-27 2017-08-08 Bend Research, Inc. Spray-drying process
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
PT2611530T (pt) 2010-09-03 2019-05-09 Bend Res Inc Aparelho de secagem por pulverização e métodos de utilização do mesmo
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
TW201306847A (zh) * 2010-11-30 2013-02-16 Vectura Ltd 組成物及用途
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
EP2812031A4 (en) * 2012-02-06 2015-11-04 Univ Iowa Res Found METHOD FOR REGULATING CFTR EXPRESSION AND PROCESSING
SG11201407676VA (en) * 2012-05-21 2015-03-30 Agency Science Tech & Res A dry powder formulation
ITMI20121052A1 (it) * 2012-06-18 2013-12-19 Ecupharma Srl Formulazioni inalatorie per la rimozione delle secrezioni viscose dall'apparato respiratorio
GB201305825D0 (en) * 2013-03-28 2013-05-15 Vectura Ltd New use
US9078853B2 (en) 2013-06-18 2015-07-14 Cmpd Licensing, Llc Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders
EP3043775B1 (en) 2013-09-11 2020-11-04 Eagle Biologics, Inc. Liquid protein formulations containing viscosity-lowering agents
BR112017003888B1 (pt) 2014-09-09 2022-11-16 Vectura Limited Método de fabricação de uma formulação de pó seco
KR102497368B1 (ko) * 2014-10-01 2023-02-10 이글 바이올로직스 인코포레이티드 점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형
JP2017538779A (ja) 2014-10-10 2017-12-28 アブリンクス・エヌ・フェー Ｒｓｖ感染の治療方法
RU2700650C2 (ru) * 2014-10-10 2019-09-18 Аблинкс Н.В. Игаляционное устройство для использования в аэрозольной терапии респираторных заболеваний
EP3212169B1 (en) 2014-10-31 2021-01-13 Bend Research, Inc. Process for forming active domains dispersed in a matrix
CN105920020B (zh) * 2016-06-23 2019-01-08 潘海英 一种治疗肺部疾病的药物组合物及其制备方法和用途
GB201611639D0 (en) 2016-07-04 2016-08-17 Ockham Biotech Ltd Delivery device and formulation
BR112019007459A2 (pt) * 2016-10-14 2019-07-16 Pulmatrix Operating Company, Inc pós secos antifúngicos
US11986448B2 (en) 2016-11-17 2024-05-21 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US11737975B2 (en) 2016-11-17 2023-08-29 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10966946B2 (en) 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
TR201722950A2 (tr) * 2017-12-29 2019-07-22 Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi Koah tedavisinde yeni farmasötik bileşimler.
IT201800007928A1 (it) * 2018-08-07 2020-02-07 Sofar Spa Composizione contenente un agente mucolitico per il trattamento di ipersecrezione di muco e dispositivo per il suo dosaggio
CN113645968A (zh) * 2019-03-18 2021-11-12 西达赛奈医疗中心 治疗胃肠疾病和障碍的组合物和方法
SG11202112719XA (en) 2019-05-16 2021-12-30 Aerovate Therapeutics Inc Imatinib formulations, manufacture, and uses thereof
KR102250876B1 (ko) * 2019-07-18 2021-05-11 충북대학교 산학협력단 티오트로피움 또는 이의 약학적으로 허용가능한 염을 포함하는 흡입용 건조분말 조성물

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4734401A (en) * 1986-03-17 1988-03-29 W. R. Grace & Co. Process for spray drying amino acid compositions
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
EP0630230B1 (en) * 1992-03-10 1996-12-04 FISONS plc Pharmaceutical inhalation compositions
US6673335B1 (en) 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5668118A (en) * 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
DE69334190T2 (de) * 1992-07-24 2008-11-27 Kennedy, Thomas P. Nicht-antikoagulierende desulfatierte Heparine als Medikamente
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
GB9313650D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6309671B1 (en) * 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma
CA2234957C (en) * 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
IL126701A (en) * 1996-04-29 2001-08-08 Dura Pharma Inc Inhaler system for inhalation of a dry powder drug
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
JP4097044B2 (ja) * 1996-07-29 2008-06-04 パリンジェニックス，インコーポレイテッド Ｏ―脱硫酸化ヘパリンで喘息を治療する方法
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US5976574A (en) * 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US20010046974A1 (en) 1997-06-06 2001-11-29 Hamilton Civic Hospitals Res Dev., Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
AU7753898A (en) * 1997-06-06 1998-12-21 Hamilton Civic Hospitals Research Development, Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
CA2209342A1 (en) 1997-06-30 1998-12-30 The University Of British Columbia Use of dextran and other oligomeric saccharides to improve airway clearance
IT1296998B1 (it) 1997-12-19 1999-08-03 Derivati Organici Lab Composizione costituita da frazioni di eparina avente caratteristiche riproducibili con peso molecolare medio di 5200 d
US20030118514A1 (en) 1998-03-26 2003-06-26 Glaxo Wellcome Inc. Compositions for inhalation
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
US6440463B1 (en) 1999-04-05 2002-08-27 Pharmaceutical Discovery Corporation Methods for fine powder formation
WO2000061178A1 (en) * 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US6560897B2 (en) * 1999-05-03 2003-05-13 Acusphere, Inc. Spray drying apparatus and methods of use
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
BR0012202A (pt) 1999-06-30 2002-04-02 Hamilton Civic Hospitals Res Composições de heparina de peso molecular médio (mmwh), método de tratamento de uma condição trombótica, método de prevenção da formação de um trombo, método de inibição da formação de trombos, composição farmacêutica, método de tratamento de trombose venosa profunda, método de prevenção de embolia pulmonar, método de preparação e usos de uma composição de mmwh
ITMI991582A1 (it) * 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
ES2161615B1 (es) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
US20020081266A1 (en) 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
AU6679300A (en) * 1999-08-26 2001-03-26 Governors Of The University Of Alberta, The Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
WO2001032144A1 (en) * 1999-10-29 2001-05-10 Inhale Therapeutic Systems, Inc. Dry powder compositions having improved dispersivity
DE19953317C1 (de) * 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
EP1129705A1 (en) * 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
CA2340836A1 (en) 2000-03-18 2001-09-18 Degussa Ag Granular product
US6369115B1 (en) * 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
US20050032745A1 (en) 2000-05-04 2005-02-10 Hamilton Civic Hospitals Res Dev., Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
CN1197587C (zh) 2000-06-09 2005-04-20 中国科学院上海细胞生物学研究所 N－位脱硫酸肝素在预防和治疗炎症中的应用
WO2002000197A1 (en) * 2000-06-27 2002-01-03 Vectura Limited Method of making particles for use in a pharmaceutical composition
US7575761B2 (en) * 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US6969705B2 (en) * 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
WO2002032406A2 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
AU1850302A (en) 2000-11-29 2002-06-11 Itoham Foods Inc Powdery preparations and proecss for producing the same
DK2283818T3 (en) 2000-11-30 2017-10-16 Vectura Ltd Process for preparing particles for use in a pharmaceutical composition
PT2283817T (pt) 2000-11-30 2016-08-22 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
ES2689704T3 (es) 2000-11-30 2018-11-15 Vectura Limited Partículas para usar en una composición farmacéutica
GB0030074D0 (en) 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
CA2429773A1 (en) * 2000-12-22 2002-07-04 Aspen Aerogels, Inc. Aerogel powder comprising therapeutic agents
GB0102902D0 (en) 2001-02-06 2001-03-21 Innovata Biomed Ltd Medicaments
GB0106403D0 (en) 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
DE10141376A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Inhalationspulvern
DE10141377A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
EP1487417A4 (en) 2001-09-17 2010-03-17 Glaxo Group Ltd DRY POWDER DRUG FORMULATIONS
US20030091513A1 (en) 2001-10-03 2003-05-15 Mohsen Nahed M. Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media
ITMI20012174A1 (it) 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
US20050123509A1 (en) 2001-10-19 2005-06-09 Lehrman S. R. Modulating charge density to produce improvements in the characteristics of spray-dried proteins
AU2002335046A1 (en) 2001-10-19 2003-05-06 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
DE60227691D1 (de) 2001-11-01 2008-08-28 Nektar Therapeutics Sprühtrocknungsverfahren
KR20050044523A (ko) 2001-11-19 2005-05-12 벡톤 디킨슨 앤드 컴퍼니 입자 형태의 약제학적 조성물
US20030166509A1 (en) 2001-11-20 2003-09-04 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery and methods of use thereof
US20060188451A1 (en) 2001-12-21 2006-08-24 Aspen Aerogels, Inc. Aerogel based pharmaceutical formulations
US20030124087A1 (en) 2001-12-26 2003-07-03 Amitie Co. Ltd. Anti-adhesion barrier
DE60323973D1 (de) * 2002-02-18 2008-11-20 Univ Southampton Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd
CA2516331C (en) * 2002-02-18 2013-04-23 University Of Southampton Combination therapy using glycosaminoglycans and therapeutic agents for the treatment of respiratory disorders
ES2527096T3 (es) * 2002-02-18 2015-01-20 Ockham Biotech Limited Combinación de ADNasa I y glucosaminoglucanos para su uso en limpieza de ADN extracelular
US20030232019A1 (en) * 2002-02-22 2003-12-18 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
FI116657B (fi) 2002-03-28 2006-01-31 Focus Inhalation Oy Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
AU2002308143A1 (en) 2002-04-12 2003-10-27 Campina Nederland Holding B.V. Excipient for use in dry powder inhalation preparations
EP1531795A4 (en) 2002-05-02 2011-02-23 Harvard College FORMULATIONS LIMITING THE EXTENSION OF PULMONARY INFECTIONS
US20050220720A1 (en) 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
US20040028746A1 (en) 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
US20040043064A1 (en) 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission
EP1556018A1 (en) 2002-09-30 2005-07-27 Acusphere, Inc. Sustained release porous microparticles for inhalation
GB0226274D0 (en) * 2002-11-11 2002-12-18 Medpharm Ltd Metered dose inhalation preparations
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
GB0300427D0 (en) 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
GB0304540D0 (en) 2003-02-27 2003-04-02 Elan Drug Delivery Ltd Particle formulation and its preparation
US6933372B2 (en) * 2003-03-07 2005-08-23 Warner-Lambert Company Method to produce a solid form of heparin
EP1635786A2 (en) 2003-05-28 2006-03-22 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat
CA2435632A1 (en) 2003-07-21 2005-01-21 Warren Hugh Finlay Formulation of powder containing nanoparticles for aerosol delivery to the lung
JP2007508240A (ja) 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
DE10339197A1 (de) 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
PL1699434T3 (pl) 2003-09-02 2011-09-30 Norton Healthcare Ltd Sposób wytwarzania leku
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
WO2005025535A2 (en) * 2003-09-15 2005-03-24 Vectura Limited Methods for preparing pharmaceutical compositions
WO2005032483A2 (en) * 2003-10-01 2005-04-14 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
WO2005041933A1 (en) * 2003-10-31 2005-05-12 Teva Pharmaceutical Industries, Ltd. Nanoparticles for drug delivery
CN1261105C (zh) * 2003-12-05 2006-06-28 吉林省辽源亚东药业股份有限公司 一种复方吡拉西坦脑蛋白水解物制剂及制备方法
GB0329208D0 (en) 2003-12-17 2004-01-21 Ici Plc Particulate materials
WO2005061089A1 (en) 2003-12-23 2005-07-07 Niro A/S A method and apparatus for producing micro particles
US7928059B2 (en) * 2004-02-24 2011-04-19 Wisconsin Alumni Research Foundation Use of neuropeptides for traumatic cartilage injury
SE528121C2 (sv) 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
RU2347574C2 (ru) * 2004-05-27 2009-02-27 Эвиджен, Инк. Способы лечения коагулопатий с использованием сульфатированных полисахаридов
US20050282775A1 (en) * 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
EP1768678A4 (en) 2004-06-30 2009-09-23 Paul L Deangelis METHODS FOR SELECTIVE TREATMENT OF DISEASES BY SPECIFIC GLYCOSAMINOGLYCAN POLYMERS
US20060014698A1 (en) * 2004-07-14 2006-01-19 O'connor Michael F Nebulized pharmaceutical compositions for the treatment of bronchial disorders
US20060078623A1 (en) 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
US9061027B2 (en) 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
MX2007009635A (es) 2005-02-10 2007-09-25 Orexo Ab Nuevas composiciones farmaceuticas utiles en la administracion transmucosa de farmacos.
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
JP2008533055A (ja) 2005-03-18 2008-08-21 ナノマテリアルズ テクノロジー ピーティーイー リミテッド 吸入剤
NZ562559A (en) 2005-05-05 2011-03-31 Sanofi Aventis Us Llc Stable nanoparticle formulations smaller than 1000 nm without the use of any surface modifier or stabilizzer absorbed onto the surface of the particles
CA2625532C (en) 2005-10-12 2013-10-01 Seikagaku Corporation Agent for applying to mucosa containing a hydrophobic group binding type glycosaminoglycan
US20070098803A1 (en) 2005-10-27 2007-05-03 Primet Precision Materials, Inc. Small particle compositions and associated methods
US7597094B2 (en) * 2005-11-29 2009-10-06 Leon Monroe Pittman Compound bow maintenance press and method for compressing a compound bow from the bow limb ends
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
US20080050444A1 (en) 2005-12-16 2008-02-28 Rajneesh Taneja Pharmaceutical compositions of ilaparazole
DE102005062270A1 (de) 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
US20070166386A1 (en) 2006-01-13 2007-07-19 Chinea Vanessa I Nanoparticle formation of pharmaceutical ingredients
KR20080105174A (ko) 2006-04-03 2008-12-03 테바 파마슈티컬 인더스트리즈 리미티드 약물 미립자
EP2007358A4 (en) 2006-04-04 2012-01-25 Stc Unm INFLATING PARTICLES FOR THE ADMINISTRATION OF A MEDICINAL PRODUCT
WO2008054508A2 (en) 2006-04-13 2008-05-08 Alza Corporation Stable nanosized amorphous drug
US20080181958A1 (en) 2006-06-19 2008-07-31 Rothrock Ginger D Nanoparticle fabrication methods, systems, and materials
WO2008002485A2 (en) 2006-06-23 2008-01-03 Alza Corporation Increased amorphous stability of poorly water soluble drugs by nanosizing
GB0617171D0 (en) 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
EP1944018A1 (en) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
US20090203789A1 (en) * 2008-01-31 2009-08-13 Multi Formulations Ltd. Fast Dissolution Amino Acid Composition

Also Published As

Publication number Publication date
CN1874757B (zh) 2011-03-09
IL173987A0 (en) 2006-07-05
CA2538399A1 (en) 2005-03-24
BRPI0414425A (pt) 2006-11-14
AU2004271778B2 (en) 2011-04-21
EP2277505A2 (en) 2011-01-26
CN1874757A (zh) 2006-12-06
AU2004271778A1 (en) 2005-03-24
WO2005025540A2 (en) 2005-03-24
WO2005025540A3 (en) 2005-06-16
RU2363448C2 (ru) 2009-08-10
NO20061254L (no) 2006-04-11
EP1663151A2 (en) 2006-06-07
US7928089B2 (en) 2011-04-19
RU2006112583A (ru) 2007-11-10
KR20060082865A (ko) 2006-07-19
US20110217339A1 (en) 2011-09-08
GB0327723D0 (en) 2003-12-31
EP2277505A3 (en) 2011-06-15
JP2007505830A (ja) 2007-03-15
NZ545550A (en) 2009-03-31
JP2012031204A (ja) 2012-02-16
JP4913595B2 (ja) 2012-04-11
US20070065373A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
SG146649A1 (en) Mucoactive agents for treating a pulmonary disease
NO20054767L (no) Sammensetninger omfattende apomorfin for inhalering i lunge
MXPA02011311A (es) Composicion novedosa.
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
AP1712A (en) Novel tiotropium-containing inhalation powder
CA2488976A1 (en) Inhalable epinephrine
PT1326595E (pt) Composicao farmaceutica compreendendo resveratrol para o tratamento de disturbios respiratorios inflamatorios
WO2003079992A3 (en) Pulmonary delivery for levodopa
MX2007012700A (es) Compuestos organicos.
WO2005113026A3 (en) Method of treating respiratory disorders and airway inflammation
WO2007082068A3 (en) Methods and compositions for treating asthma in human and non human primates
UA83813C2 (ru) Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
WO2004043392A3 (en) Mucin synthesis inhibitors
IL165378A0 (en) Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
HK1074582A1 (en) Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
WO2004113286A3 (en) Mucin synthesis inhibitors
HK1078795A1 (en) Powder formulations suitable for inhalation
ZA200704921B (en) Sulfonyl amino cyclic derivatives and use thereof
EA200500864A1 (ru) Новый, содержащий тиотропий порошковый препарат для ингаляции
MXPA04007294A (es) Composicion para inhalacion.
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
WO2004103364A3 (en) Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
WO2004069195A3 (en) Methods and compositions for treating inflammatory disorders of the airways